Amneal expands portfolio with addition of icosapent ethyl acid soft gel capsules

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) and strides pharma science limited (“strides”) today announced the addition of icosapent ethyl acid soft gel capsules, a product referencing vascepa®. the product has been in-licensed from strides, a global pharmaceutical manufacturer, and will be commercialized by amneal starting in the fourth quarter of 2023. icosapent ethyl acid soft gel capsules 0.5g and 1g is an ethyl ester of eicosape.
AMRX Ratings Summary
AMRX Quant Ranking